Evidence map›Paper›PMID 40853936›Full record

ArticlePLOS global public health2025

Usability and acceptability of a novel TB infection diagnostic test among key populations in Mexicali.

Amanda Brumwell, Rosa Herrera, Kevin Contreras, Mildred Lee, Eduardo Becerra, Julia Estrada-Guzmán, Thomas Nicholson, Rene Machado Contreras, Meredith Brooks

Abstract read
In one paragraph

Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amanda BrumwellDepartment of Global Health, University of Washington School of Public Health, Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0002-5766-7012
Rosa HerreraMexicali Health Jurisdiction Tuberculosis Program, Mexicali, Baja California, Mexico.
Kevin ContrerasMexicali Health Jurisdiction Tuberculosis Program, Mexicali, Baja California, Mexico.
Mildred LeeMexicali Health Jurisdiction Tuberculosis Program, Mexicali, Baja California, Mexico.
Eduardo BecerraMexicali Health Jurisdiction Tuberculosis Program, Mexicali, Baja California, Mexico.
Julia Estrada-GuzmánMexicali Health Jurisdiction Tuberculosis Program, Mexicali, Baja California, Mexico.
Thomas NicholsonAdvance Access & Delivery, Inc, Durham, North Carolina, United States of America.
Rene Machado ContrerasUniversidad Autónoma de Baja California, Mexicali, Baja California, Mexico.
Meredith BrooksDepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0001-8431-5517

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculin skin test (TST) remains the standard-of-care test for TB infection in many high TB-burden settings. Despite existing diagnostics overcoming challenges associated with TST implementation, there has been poor uptake programmatically. We conducted formative research into patients' and providers' perceptions of acceptability and usability of a novel IGRA test, called QIAreach QuantiFERON TB (or, QIAreach), compared to TST in a programmatic setting in Mexicali. Programmatic outreach to screen for TB disease and infection was conducted in Mexicali (December 2020-July 2021). A 5-point Likert scale survey was administered to two groups at high risk of TB infection-people who use drugs (PWUD) and household contacts (HHC) of TB patients-and who received testing via TST and QIAreach. This survey evaluated patients' comparative preferences for the two tests. Additionally, a modified system usability scale was administered to TB program staff involved in the administration and processing of TST and IGRA tests pre- and post-QIAreach implementation to measure the tests' perceived usability. Of 201 patients, 103 (51.2%) were PWUD and 98 (48.8%) were HHCs. The acceptability survey found that the blood draw for QIAreach was preferred to, and more trustworthy than, the injection for TST. Also, only requiring one visit with providers for QIAreach was preferred among HHCs, but comparatively less preferable for PWUD. In-person delivery of test results was preferable and more trustworthy. The majority preferred QIAreach over TST; though this was higher among PWUD. Nine staff completed the usability survey. Perceived usability before implementing the IGRA remained nearly constant from the pre-implementation timepoint (SUS Score: 52.5, IQR: 45-65) to the post-implementation timepoint (50, IQR: 45-52.5, p = 0.31). IGRA was more acceptable to patients, and perceived usability was mixed among staff. Patient and provider preferences must be considered when integrating novel IGRA tests into settings where TST is routinely used.

Identifiers

PMID40853936
PMCPMC12377580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.